XORTX board chairman Anthony Giovinazzo resigns
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Alaska LNG shipping savings justifies billions in investment, developer says
- Citi cuts investment banking analyst program to two years - Bloomberg
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- Paramount Skydance to close WBD deal, change ticker to SKYD
XORTX Announces Director Resignation
July 31, 2026 5:00 PM EDTCALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that Anthony Giovinazzo is stepping down from the board of directors for personal reasons and to pursue other interests.
Dr. Allen Davidoff, co-CEO of XORTX, stated, XORTX management and the board of directors extends our heartfelt appreciation for Mr. Giovinazzos efforts as chairman of the... More



